JP2009506978A5 - - Google Patents

Info

Publication number

JP2009506978A5

JP2009506978A5 JP2008508028A JP2008508028A JP2009506978A5 JP 2009506978 A5 JP2009506978 A5 JP 2009506978A5 JP 2008508028 A JP2008508028 A JP 2008508028A JP 2008508028 A JP2008508028 A JP 2008508028A JP 2009506978 A5 JP2009506978 A5 JP 2009506978A5

Authority

JP

Japan

Prior art keywords

insulin

phase

component

pharmaceutical

linkage

Prior art date

2006-04-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 185
• 102000004877 Insulin Human genes 0.000 claims 90
• 108090001061 Insulin Proteins 0.000 claims 90
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 83
• 229940125396 insulin Drugs 0.000 claims 81
• 239000008194 pharmaceutical composition Substances 0.000 claims 43
• 229960003237 betaine Drugs 0.000 claims 41
• 239000004026 insulin derivative Substances 0.000 claims 31
• 239000000203 mixture Substances 0.000 claims 27
• 108010026951 Short-Acting Insulin Proteins 0.000 claims 18
• 229940123958 Short-acting insulin Drugs 0.000 claims 18
• 239000004615 ingredient Substances 0.000 claims 11
• 102000016261 Long-Acting Insulin Human genes 0.000 claims 9
• 108010092217 Long-Acting Insulin Proteins 0.000 claims 9
• 229940100066 Long-acting insulin Drugs 0.000 claims 9
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 8
• 229940123208 Biguanide Drugs 0.000 claims 8
• 230000003111 delayed effect Effects 0.000 claims 8
• 239000011324 bead Substances 0.000 claims 6
• 239000011248 coating agent Substances 0.000 claims 6
• 238000000576 coating method Methods 0.000 claims 6
• 239000002245 particle Substances 0.000 claims 6
• 238000013270 controlled release Methods 0.000 claims 5
• 239000002552 dosage form Substances 0.000 claims 5
• 230000004888 barrier function Effects 0.000 claims 4
• 239000008280 blood Substances 0.000 claims 4
• 210000004369 blood Anatomy 0.000 claims 4
• 150000002148 esters Chemical class 0.000 claims 4
• 239000002243 precursor Substances 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 229920003176 water-insoluble polymer Polymers 0.000 claims 3
• 229940122254 Intermediate acting insulin Drugs 0.000 claims 2
• 238000002288 cocrystallisation Methods 0.000 claims 2
• 150000001875 compounds Chemical class 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 238000013265 extended release Methods 0.000 claims 2
• 238000001727 in vivo Methods 0.000 claims 2
• 230000002797 proteolythic effect Effects 0.000 claims 2
• 238000013268 sustained release Methods 0.000 claims 2
• 239000012730 sustained-release form Substances 0.000 claims 2
• 108010065920 Insulin Lispro Proteins 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
• 229920001577 copolymer Polymers 0.000 claims 1
• 239000013078 crystal Substances 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 1
• 238000001802 infusion Methods 0.000 claims 1
• 229960002068 insulin lispro Drugs 0.000 claims 1
• 239000012528 membrane Substances 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 239000008177 pharmaceutical agent Substances 0.000 claims 1
• 230000000144 pharmacologic effect Effects 0.000 claims 1
• 230000000717 retained effect Effects 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1